Bridgebio Pharma Inc (BBIO)

$44.45 +2.28 (5.41%)
Market Cap 8.01B
Revenue (ttm) 221.90M
Net Income (ttm) -535.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -241.44%
Debt to Equity Ratio -1.13
Volume 3,815,200
Avg Vol 2,950,818
Day's Range N/A - N/A
Shares Out 189.88M
Stochastic %K 95%
Beta 1.11
Analysts Strong Sell
Price Target $58.39

Company Profile

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 doub...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 391 9740
Address:
3160 Porter Drive, Suite 250, Palo Alto, United States
trading_momentum
trading_momentum Jun. 25 at 4:04 AM
$BBIO breaking out, next PT 48
0 · Reply
CPKC
CPKC Jun. 24 at 10:09 PM
$BBIO there will be a day where we all wished we would’ve bought more
0 · Reply
WAJeff
WAJeff Jun. 24 at 9:05 PM
$BBIO Late to this, added $44.40
1 · Reply
RonIsWrong
RonIsWrong Jun. 24 at 8:40 PM
$BBIO not bad. more coming
2 · Reply
Reanimated666
Reanimated666 Jun. 24 at 8:22 PM
$BBIO
0 · Reply
Jblack500
Jblack500 Jun. 24 at 6:37 PM
$GENI $BBIO $AAOI $CRDO $CCJ SOFI Let's close strong. A lot of money out there being made today on the long side. Hope you all are killing it today
0 · Reply
roger120
roger120 Jun. 24 at 6:12 PM
$BBIO chart challenge. Show a better chart that's set to run? $OKLO $PLTR $ASTS (bedsides these 3)
1 · Reply
Pika_Capital
Pika_Capital Jun. 24 at 4:28 PM
$BBIO this was a no brainer add actually
1 · Reply
Reanimated666
Reanimated666 Jun. 24 at 3:29 PM
$BBIO
0 · Reply
LMXPERTEN
LMXPERTEN Jun. 24 at 3:18 PM
$BBIO 🚂
0 · Reply
Latest News on BBIO
BridgeBio: New Data Bolsters The Bull Case

Jun 4, 2025, 3:34 AM EDT - 20 days ago

BridgeBio: New Data Bolsters The Bull Case

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 22 days ago

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

May 20, 2025, 7:30 AM EDT - 5 weeks ago

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

May 19, 2025, 12:33 PM EDT - 5 weeks ago

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 4:01 PM EDT - 5 weeks ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

May 13, 2025, 7:30 AM EDT - 6 weeks ago

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

May 12, 2025, 7:30 AM EDT - 6 weeks ago

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

May 7, 2025, 7:30 AM EDT - 6 weeks ago

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:43 PM EDT - 2 months ago

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 4:01 PM EDT - 2 months ago

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

Apr 28, 2025, 5:00 AM EDT - 2 months ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BridgeBio: Early Signs Point To Blockbuster Revenues

Apr 22, 2025, 11:14 AM EDT - 2 months ago

BridgeBio: Early Signs Point To Blockbuster Revenues

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Apr 22, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Mar 31, 2025, 10:00 AM EDT - 3 months ago

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

Mar 27, 2025, 3:20 PM EDT - 3 months ago

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

AZN

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

Mar 27, 2025, 7:00 AM EDT - 3 months ago

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Mar 24, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

BridgeBio Announces CFO Succession

Mar 17, 2025, 4:01 PM EDT - 3 months ago

BridgeBio Announces CFO Succession

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Feb 26, 2025, 2:49 AM EST - 4 months ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Feb 24, 2025, 4:09 PM EST - 4 months ago

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

BridgeBio: Strong Start For Attruby

Feb 20, 2025, 1:34 PM EST - 4 months ago

BridgeBio: Strong Start For Attruby

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

Feb 20, 2025, 7:30 AM EST - 4 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

Feb 13, 2025, 4:01 PM EST - 4 months ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Feb 11, 2025, 9:21 AM EST - 4 months ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Top 4 Health Care Stocks You May Want To Dump In Q1

Jan 21, 2025, 6:06 AM EST - 5 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BSX ISRG ITCI

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Jan 15, 2025, 9:30 AM EST - 5 months ago

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

Jan 14, 2025, 3:40 PM EST - 5 months ago

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Jan 13, 2025, 11:00 AM EST - 5 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Jan 8, 2025, 11:13 AM EST - 5 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BMY IOVA LLY MDGL MRK PFE

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:30 AM EST - 5 months ago

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Dec 13, 2024, 7:18 AM EST - 6 months ago

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

Dec 3, 2024, 8:00 AM EST - 7 months ago

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

Nov 25, 2024, 9:03 AM EST - 7 months ago

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

PFE

BridgeBio: Next Chapter Begins After Attruby Approval

Nov 24, 2024, 3:48 PM EST - 7 months ago

BridgeBio: Next Chapter Begins After Attruby Approval

US FDA approves BridgeBio's drug for rare heart condition

Nov 22, 2024, 7:25 PM EST - 7 months ago

US FDA approves BridgeBio's drug for rare heart condition

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Nov 22, 2024, 7:11 PM EST - 7 months ago

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Nov 19, 2024, 2:44 PM EST - 7 months ago

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

Nov 18, 2024, 11:15 AM EST - 7 months ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

Nov 18, 2024, 8:00 AM EST - 7 months ago

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

Nov 18, 2024, 5:30 AM EST - 7 months ago

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

Nov 14, 2024, 10:41 AM EST - 7 months ago

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management

Nov 5, 2024, 7:30 AM EST - 8 months ago

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors

Oct 30, 2024, 8:00 AM EDT - 8 months ago

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

Oct 24, 2024, 7:30 AM EDT - 8 months ago

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

Oct 3, 2024, 7:30 AM EDT - 9 months ago

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

Sep 30, 2024, 1:17 PM EDT - 9 months ago

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Sep 30, 2024, 7:30 AM EDT - 9 months ago

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

Sep 27, 2024, 6:00 PM EDT - 9 months ago

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

Sep 17, 2024, 7:30 AM EDT - 10 months ago

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

trading_momentum
trading_momentum Jun. 25 at 4:04 AM
$BBIO breaking out, next PT 48
0 · Reply
CPKC
CPKC Jun. 24 at 10:09 PM
$BBIO there will be a day where we all wished we would’ve bought more
0 · Reply
WAJeff
WAJeff Jun. 24 at 9:05 PM
$BBIO Late to this, added $44.40
1 · Reply
RonIsWrong
RonIsWrong Jun. 24 at 8:40 PM
$BBIO not bad. more coming
2 · Reply
Reanimated666
Reanimated666 Jun. 24 at 8:22 PM
$BBIO
0 · Reply
Jblack500
Jblack500 Jun. 24 at 6:37 PM
$GENI $BBIO $AAOI $CRDO $CCJ SOFI Let's close strong. A lot of money out there being made today on the long side. Hope you all are killing it today
0 · Reply
roger120
roger120 Jun. 24 at 6:12 PM
$BBIO chart challenge. Show a better chart that's set to run? $OKLO $PLTR $ASTS (bedsides these 3)
1 · Reply
Pika_Capital
Pika_Capital Jun. 24 at 4:28 PM
$BBIO this was a no brainer add actually
1 · Reply
Reanimated666
Reanimated666 Jun. 24 at 3:29 PM
$BBIO
0 · Reply
LMXPERTEN
LMXPERTEN Jun. 24 at 3:18 PM
$BBIO 🚂
0 · Reply
RonIsWrong
RonIsWrong Jun. 24 at 3:08 PM
$BBIO carry on!
0 · Reply
KWalzz
KWalzz Jun. 24 at 3:01 PM
$BBIO so I'm up 40% now from April, 7th when I bought in as a hedge to the super-loser $DVAX (down 20%) ... see, Myers and Spencer what a real gem in bio world delivers to its shareholders when good people steer the ship.
0 · Reply
PenkeTrading
PenkeTrading Jun. 24 at 2:31 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of BridgeBio Pharma Inc. Is that bullish or bearish? $BBIO #BridgeBio #RsiOverbought #NASDAQ
0 · Reply
TipRanks
TipRanks Jun. 24 at 10:14 AM
TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box https://www.tipranks.com/news/article/tipranks-perfect-10-picks-2-top-scoring-stocks-that-are-ticking-every-box $GDS $BBIO
0 · Reply
trading_momentum
trading_momentum Jun. 24 at 4:53 AM
$BBIO as well peaking above resistance on the weekly
0 · Reply
roger120
roger120 Jun. 24 at 4:06 AM
$BBIO it has checked many boxes for growth. BO or not, it will get its $110 whether by acquisition or independent growth. Next earnings will be 🚀🚀🚀 P3 DATA WILL 🚀🚀🚀
0 · Reply
gpaisa
gpaisa Jun. 24 at 3:04 AM
$BBIO no one talks about it, just quietly building and breaking through the base.
1 · Reply
Jblack500
Jblack500 Jun. 23 at 8:21 PM
$BBIO $EXEL Movin' on up to the east side
0 · Reply
Jblack500
Jblack500 Jun. 23 at 10:41 AM
$EXEL $BBIO $GILD $SMMT $ABBV with this zanza readout, exelixis becomes a top buyout candidate for large cap bio. Strong revenue already and now you are seeing the next stage of what will be a major revenue producing drug to add to the bottom line show up with P3 trial win. Patent cliffs are critical for companies like Merck and bmy, etc. Exel would be a meaningful acquisition, now. I've been in on several already-array biopharma,celgene, pharmacyclics. I see EXEL now as #1 takeout for oncology
1 · Reply
Nomorelies
Nomorelies Jun. 23 at 3:19 AM
$BBIO Hold strong!
0 · Reply
DonCorleone77
DonCorleone77 Jun. 23 at 1:20 AM
$BBIO $XBI Btw, this is another account I forgot to mention in my post last Friday. If you aren't following @TrendEdgeLogan, you might want to consider doing so. This guy consistently has really useful information.
2 · Reply
roger120
roger120 Jun. 22 at 7:14 PM
$BBIO i think the decision to sell at 60 has sailed. They are now positioned to grow into a $30B company by 2030. They shouldn't sell for anything less than $110 per share if BO before P3 data. After p3 data $130 or more. This is one of the tickers that the market hasn't realized their full potential. (As opposed to ALNY)
1 · Reply